港股异动 | 三生制药(01530)升8% 特比澳儿童ITP适应症申报上市国信维持“买入”

智通财经2022-11-21

智通财经APP获悉，三生制药(01530)再度显著走强，早盘升约8%。近日，公司核心产品特比澳新上市申请获NMPA受理，用于治疗儿童或青少年ITP。今年上半年，特比澳营收占比达50.95%。国信指，公司盈利能力强，现金流充沛，维持“买入”。截至发稿，三生制药涨8.29%，报7.45港元，成交额0.93亿港元。近日，三生制药宣布，公司向NMPA提交的重组人血小板生成素注射液（特比澳）新上市申请获得...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2285333015?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2022-11-21 11:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2285333015","market":"us","top_or_hot":-1,"title":"港股异动 | 三生制药(01530)升8% 特比澳儿童ITP适应症申报上市 国信维持“买入”","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，三生制药(01530)再度显著走强，早盘升约8%。近日，公司核心产品特比澳新上市申请获NMPA受理，用于治疗儿童或青少年ITP。今年上半年，特比澳营收占比达50.95%。国信指，公司盈利能力强，现金流充沛，维持“买入”。截至发稿，三生制药涨8.29%，报7.45港元，成交额0.93亿港元。近日，三生制药宣布，公司向NMPA提交的重组人血小板生成素注射液（特比澳）新上市申请获得...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/834356.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 三生制药(01530)升8% 特比澳儿童ITP适应症申报上市 国信维持“买入”</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 三生制药(01530)升8% 特比澳儿童ITP适应症申报上市 国信维持“买入”\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-11-21 11:22 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/834356.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，三生制药(01530)再度显著走强，早盘升约8%。近日，公司核心产品特比澳新上市申请获NMPA受理，用于治疗儿童或青少年ITP。今年上半年，特比澳营收占比达50.95%。国信指，公司盈利能力强，现金流充沛，维持“买入”。截至发稿，三生制药涨8.29%，报7.45港元，成交额0.93亿港元。近日，三生制药宣布，公司向NMPA提交的重组人血小板生成素注射液（特比澳）新上市申请获得...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/834356.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/834356.html","article_id":"2285333015","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2285333015","pubTimestamp":1669000954,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，三生制药再度显著走强，早盘升约8%。近日，公司核心产品特比澳新上市申请获NMPA受理，用于治疗儿童或青少年ITP。截至发稿，三生制药涨8.29%，报7.45港元，成交额0.93亿港元。今年上半年，特比澳实现销售15.75亿元，在公司收入中占比约51%。公司盈利能力强，现金流充沛，维持“买入”评级。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","BK1583":"高瓴概念","ITP":"IT科技包装","BK4199":"纸制品","BK1593":"医美概念股","01530":"三生制药"},"translate_title":"Hong Kong stocks changed Sansheng Pharmaceutical (01530) rose by 8%. Tebi'ao children's ITP indications were declared for listing. Guoxin maintained \"buy\"","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1,"ITP":1,"SSRX":1},"content_text":"智通财经APP获悉，三生制药(01530)再度显著走强，早盘升约8%。近日，公司核心产品特比澳新上市申请获NMPA受理，用于治疗儿童或青少年ITP。今年上半年，特比澳营收占比达50.95%。国信指，公司盈利能力强，现金流充沛，维持“买入”。截至发稿，三生制药涨8.29%，报7.45港元，成交额0.93亿港元。近日，三生制药宣布，公司向NMPA提交的重组人血小板生成素注射液（特比澳）新上市申请获得受理，用于治疗儿童或青少年的持续性或慢性原发免疫性血小板减少症（ITP）。今年上半年，特比澳实现销售15.75亿元，在公司收入中占比约51%。此前，国信证券点评指，公司特比澳等生物制药板块核心产品销售稳定，同时，毛发健康领域的核心产品蔓迪有望成为国内唯一获批上市的米诺地尔泡沫剂型。公司盈利能力强，现金流充沛，维持“买入”评级。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2285333015"}

港股异动 | 三生制药(01530)升8% 特比澳儿童ITP适应症申报上市 国信维持“买入”

精彩评论

港股异动 | 三生制药(01530)升8% 特比澳儿童ITP适应症申报上市国信维持“买入”